Peto1980 {bayesmeta}R Documentation

Aspirin after myocardial infarction example data


Numbers of cases (patients) and events (deaths) in treatment and control groups of six studies.




The data frame contains the following columns:

publication character publication identifier
treat.cases numeric number of cases in treatment group numeric number of events in treatment group
control.cases numeric number of cases in control group numeric number of events in control group


Quoting from Brockwell and Gordon (2001): “The collection consists of six studies, each examining the effect of aspirin after myocardial infarction. In each study the number of patients who died after having been given either aspirin or a control drug is recorded.”


S.E. Brockwell, I.R. Gordon. A comparison of statistical methods for meta-analysis. Statistics in Medicine, 20(6):825-840, 2001. doi: 10.1002/sim.650.


R. Peto. Aspirin after myocardial infarction. The Lancet, 315(8179):1172-1173, 1980. doi: 10.1016/S0140-6736(80)91626-8.

P.C. Elwood, A.L. Cochrane, M.L.Burr, P.M. Sweetnam, G. Williams, E. Welsby, S.J. Hughes, R. Renton. A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. British Medical Journal, 1(5905):436-440, 1974. doi: 10.1136/bmj.1.5905.436.

The Coronary Drug Project Research Group. Aspirin in coronary heart disease. Journal of Chronic Diseases, 29(10):625-642, 1976. doi: 10.1016/0021-9681(76)90020-5.

K. Breddin, D. Loew, K. Lechner, K. Ueberla, E. Walter. Secondary prevention of myocardial infarction: a comparison of acetylsalicylic acid, placebo and phenprocoumon. Haemostasis, 9(6):325-344, 1980. doi: 10.1159/000214375.

P.C. Elwood, P.M. Sweetnam. Aspirin and secondary mortality after myocardial infarction. The Lancet, 314(8156):1313-1315, 1979. doi: 10.1016/S0140-6736(79)92808-3.

Aspirin Myocardial Infarction Study Research Group. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. Journal of the American Medical Association, 243(7):661-669, 1980. doi: 10.1001/jama.1980.03300330019023.

The Persantine-Aspirin Reinfarction Study Research Group. Persantine and aspirin in coronary heart disease. Circulation, 62(3):449-461, 1980. doi: 10.1161/01.CIR.62.3.449.


## Not run: 
# compute effect sizes (log odds ratios) from count data
# (using "metafor" package's "escalc()" function):
require("metafor") <- escalc(measure="OR",
        ,   n1i=treat.cases,
        , n2i=control.cases,
                  slab=publication, data=Peto1980)

# check sensitivity to different prior choices:
peto.ma01 <- bayesmeta(
peto.ma02 <- bayesmeta(, tau.prior=function(t){dhalfnormal(t, scale=1)})
  plot(peto.ma01, which=4, prior=TRUE, taulim=c(0,1), main="uniform prior")
  plot(peto.ma02, which=4, prior=TRUE, taulim=c(0,1), main="half-normal prior")

# compare heterogeneity (tau) estimates:
print(rbind("uniform"    =peto.ma01$summary[,"tau"],

# compare effect (mu) estimates:
print(rbind("uniform"    =peto.ma01$summary[,"mu"],


## End(Not run)

[Package bayesmeta version 2.7 Index]